SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Attention centers on CRISPR Therapeutics CTX310 clinical data and other pipeline readouts, with traders debating whether encouraging results can shift sentiment toward its in-vivo gene-editing and autoimmune programs. Optimism about the catalysts and Casgevys commercial ramp is tempered by frustration that the stock has remained range-bound and may not respond to positive developments.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could decline sharply through 2027 has weighed on CRMD, intensifying concerns about pricing and revenue from its flagship product. Traders disagree on how decisive the warning is: some view DaVitas estimates as preliminary and point to CMS reimbursement and adoption as offsets, while others see lasting pressure on the business outlook.

Starbucks Corp. engages in the production, marketing, and retailing of specialty coffee. It operates through the following segments: North America, International, and Channel Development. The North America segment focuses on the United States and Canada. The International segment is involved in China, Japan, Asia Pacific, Europe, Middle East, Africa, Latin America, and Caribbean. The Channel Development segment includes roasted whole bean and ground coffees, Seattle’s Best Coffee, and Teavana-branded single-serve products. The company was founded by Jerry Baldwin and Howard D. Schultz on November 4, 1985, and is headquartered in Seattle, WA.

Starbucks Corp.

Starbucks Corp

Starbucks quarterly results sparked debate after stronger-than-expected earnings and comparable sales were offset by a revenue miss, with the China restructuring weighing on reported sales and the stocks reaction remaining subdued. Bulls point to improving U.S. traffic and the turnaround outlook, while bears question the valuation and whether growth can justify it.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Takeover speculation has fueled attention after reports that Lundbeck explored acquiring Xeris, though the company said it is not for sale and traders disagree on whether a deal is likely. The discussion also centers on upcoming quarterly results and the longer-term potential of Recorlev growth and XP-8121s planned Phase 3 program.

BNB (BNB) is a cryptocurrency . BNB has a current supply of 131,511,387.69. The last known price of BNB is 703.59425696 USD and is up 0.47 over the last 24 hours. It is currently trading on 3523 active market(s) with $2,735,089,335.64 traded over the last 24 hours. More information can be found at https://bnbchain.org/en.

Binance

A reported multibillion-dollar Binance security breach is driving attention, with traders focused on suspended withdrawals and concerns about exchange security and customer funds. The community debates whether Binance can cover the losses and whether BNBs limited decline understates the risk; claims of an inside job or specific perpetrators remain speculation.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Traders are split on Disneys choppy, range-bound trading, with bullish breakout and call-positioning talk countered by bearish bets on a pullback. Some posts also react negatively to allegations involving the company, but the discussion does not establish them as a confirmed market catalyst.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Ciscos decline is being tied to an analyst price-target cut amid concerns that networking growth may be peaking and the stocks valuation could compress; the firm kept its rating unchanged. Traders are split between calling the selloff an overreaction given AI-networking demand and seeing continued technical weakness.

Invesco Exchange-Traded Fund Trust - Invesco S&P 500 Equal Weight ETF

Invesco S&P 500 Equal Weight ETF

RSP is drawing attention as a gauge of market breadth and the rotation between mega-cap tech and the broader S&P 500: traders have highlighted periods of equal-weight outperformance as participation widens beyond AI and tech leaders. The reaction is mixed, with some viewing the rotation as healthy broadening and others warning that recent RSP weakness signals deteriorating breadth and renewed concentration in a few large stocks.

Pudgy Penguins (PENGU) is a cryptocurrency launched in 2024and operates on the Solana platform. Pudgy Penguins has a current supply of 76,724,221,264.3 with 62,860,396,090.04 in circulation. The last known price of Pudgy Penguins is 0.00754361 USD and is up 6.59 over the last 24 hours. It is currently trading on 540 active market(s) with $130,377,930.32 traded over the last 24 hours. More information can be found at https://www.pengu.pudgypenguins.com.

Pudgy Penguins

PENGU is drawing attention around its pullback and attempts to hold a technical support zone, with traders debating whether it can rebound or break lower. Dip buyers point to possible support and broader crypto-market recovery, while bears cite persistent selling, weak momentum and a lack of fresh catalysts.

Barrick Mining Corp. engages in the production and sale of gold, copper, and related activities. It also provides exploration and mining development. It operates through the following business segments: Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, Bulyanhulu, and Other Mines. The company was founded by Peter D. Munk in 1983 and is headquartered in Toronto, Canada.

Barrick Mining Corp.

Barrick Mining Corp

Barrick is drawing attention as its shares and the wider mining sector face pressure, with repeated technical analysis suggesting the correction may not be over. Traders are divided between expecting further weakness and treating the pullback as an opportunity to add, while gold-price and interest-rate concerns weigh on near-term sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TGTX Stock Hits Fresh 52-Week High Ahead Of Earnings Amid Buyout Buzz

Equity

Investors are now focused on the company’s projected third-quarter 2026 results, estimated for Monday, November 2.


ENPH Stock Drops After-Hours As Interest Rates And Tax Credit Expiry Hit US Solar Demand

CEO Badri Kothandaraman attributed the drop in U.S. sell-through to elevated interest rates and the expiration of tax credits on renewable energy system installations. 


SEDG Stock Slides After Deutsche Bank Tags It A Short-Term Sell

Deutsche Bank analyst Corinne Blanchard said elevated interest rates are weighing on SolarEdge products’ U.S. demand and sees risk to fourth-quarter and 2027 earnings.

ACAD Stock Clocks Worst Day In 2 Years After Alzheimer’s Psychosis Drug Misses Main Goal — Citi Cuts Drug’s Success Odds To 20%  

Citi’s Yigal Nochomovitz trimmed his price target to $33 from $40 and kept a Buy rating following the company’s update.


KMX Stock Edges Higher: CarMax Shares Bounce As 145 Corporate Jobs Go Ahead Of Q2 Report

The company has cut 145 jobs or 4% of its corporate staff, The Wall Street Journal reported. 


AMRX Stock Advances As Generic To Ipsen’s Hormone Shot Gets FDA Nod 

The Food and Drug Administration (FDA) cleared a 120-milligram prefilled syringe that copies Ipsen’s Somatuline Depot, a long-acting under-the-skin injection.


WEN Stock Drops After Meritage Files For Bankruptcy — Will More Stores Close Next?  

One of Wendy’s franchisees, operating 314 Wendy’s restaurants across 15 states, or about 5% of Wendy’s U.S. system, filed a voluntary Chapter 11 petition on Thursday. 


Should iShares Core S&P Small-Cap ETF (IJR) Be on Your Investing Radar?

American Eagle Drops Big Ad Campaigns, Chases the Checkout 

American Eagle posted a quarterly profit beat that leaned on a $161 million tariff refund on Wednesday. 


Why Is KNTK Stock Up 5% After-Hours? 

People familiar with the matter told Bloomberg that Kinetik is in the early stages of exploring alternatives and is working with advisers to prepare a potential sale process. 


iShares Trust - iShares Core S&P Small-Cap ETF

Neutral Sentiment

<ul class="summary-bullets"><li>According to data from Fiscal AI, analysts forecast roughly $0.36 in earnings per share and about $245 million in revenue.</li><li>In late August, rumors emerged that a U.S. biopharma with a market cap between $20 billion and $40 billion may be interested in acquiring TG Therapeutics; the company didn't confirm the rumors.&nbsp;</li><li>Besides commercializing intravenous Briumvi, TG &nbsp;is also testing a subcutaneous version of the drug and a CAR-T therapy azer-cel.</li></ul> Shares of TG Therapeutics (TGTX) jumped on Friday, setting a new 52-week high, advancing a multi-day climb ahead of the company’s third-quarter earnings and amid buyout rumors. &nbsp;The stock was trading 5% higher at the time of writing.<h2 class="st-heading-2">TGTX’s Upcoming Earnings</h2>Investors are now focused on the company’s projected third-quarter 2026 results, estimated for Monday, November 2. The company has not confirmed the date.According to data from Fiscal AI, analysts forecast roughly $0.36 in earnings per share and about $245 million in revenue. In the prior quarter, the company beat revenue expectations but missed on EPS while raising full-year guidance on BRIUMVI sales.BRIUMVI is the company’s sole approved product indicated for adults with relapsing forms of multiple sclerosis, a chronic, autoimmune disease of the central nervous system causing nerve damage. It is given as a one-hour intravenous infusion every 24 weeks after the initial doses and has gained regulatory clearance in the United States and several other markets. Recent quarterly results showed continued double-digit sequential growth in U.S. net sales, supporting raised annual revenue targets near $950 million globally.<h2 class="st-heading-2">TG Therapeutics’ Pipeline Updates</h2>Besides commercializing intravenous Briumvi, TG &nbsp;is also testing a subcutaneous version of the drug and a CAR-T therapy, azer-cel.On October 23, the company presented early-stage data for azer-cel in progressive multiple sclerosis at the MSToronto2026 meeting. In 26 treated participants, the regimen showed no high-grade CAR-T toxicities. Among evaluable patients, 89% had stable or improved disability scores at day 90, with evidence of B-cell depletion in blood and cerebrospinal fluid.According to data from Koyfin, seven of eight analysts covering TGTX rate it 'Buy' or higher, while one rates it 'Strong Sell.' The stock has a 12-month average price target of $69.71, representing a potential upside of over 10% from the stock’s last close.In late August, rumors emerged that a U.S. biopharma with a market cap between $20 billion and $40 billion may be interested in acquiring TG Therapeutics. The company didn't confirm the rumors.<h2 class="st-heading-2">How Did Stocktwits Retail Traders React?</h2>On Stocktwits, retail sentiment around <a class="mention" data-mention="$TGTX" data-symbol-id="TGTX" href="https://stocktwits.com/symbol/TGTX" target="_blank">TGTX stock</a> jumped from 'bullish' to 'extremely bullish' territory over the past 24 hours, while message volume stayed at 'high' levels.A Stocktwits user voiced anticipation for a buyout for $15-$20 billion, noting that he is “not convinced, but it is possible.” He also highlighted the strong addressable market for Briumvi, once the subcutaneous version of the drug is also approved. Currently, only the intravenous version is commercially available; the subcutaneous version is in late-stage development.<stembedurl>https://stocktwits.com/CT_Biker/message/667783391</stembedurl>Another user, however, pinned the rally to good earnings instead of buyout anticipation.<stembedurl>https://stocktwits.com/DonutHole2/message/667775080</stembedurl>TGTX has more than doubled year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/door-dash-s-17-b-instacart-deal-draws-significant-street-attention-a-look-at-what-analysts-have-to-say/cZULGnnR9T6">DoorDash’s $17B Instacart Deal Draws Significant Street Attention – A Look At What Analysts Have To Say</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the TG Therapeutics logo is displayed on the screen of a smart tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Investors are now focused on the company’s projected third-quarter 2026 results, estimated for Monday, November 2.

iShares Core S&P Small-Cap ETF

TG Therapeutics Inc

Vanguard Total Stock Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$140.29
Prev Close	$142.01
Open	$141.35
Dividend Yield	N/A
50-Day Moving Average	$140.25
Beta	N/A
Avg. Volume	3.38M
PE Ratio	N/A

52-Week High	$150.69
52-Week Low	$112.00
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

IJR Fundamentals